Form 4 for XLO Xilio Therapeutics, Inc.
Accepted 2021-10-28 00:00:00 ET · period of report 2021-10-26 · accession 0000315066-21-001812 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2021-10-28 | 2021-10-26 | XLO | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +1.88M | 815.8K | New | — |
| DMI | 2021-10-28 | 2021-10-26 | XLO | FMR LLC | See Remark 1 | C - Cnv Deriv | — | -17.87M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-26 | C | A | 4,465 | — | 4,465 | I F-Prime Capital Partners Healthcare Advisors Fund IV LP | — | — | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 2 | Common | Common Stock | 2021-10-26 | C | A | 686,499 | — | 1,502,287 | I F-Prime Capital Partners Healthcare Fund IV LP | — | — | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 3 | Common | Common Stock | 2021-10-26 | C | A | 28,703 | — | 1,530,990 | I F-Prime Capital Partners Healthcare Fund IV LP | — | — | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 4 | Common | Common Stock | 2021-10-26 | C | A | 372,215 | — | 372,215 | I Impresa Fund III Limited Partnership | — | — | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 5 | Common | Common Stock | 2021-10-26 | C | A | 789,473 | — | 815,788 | I F-Prime Capital Partners Healthcare Fund IV LP | — | — | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 6 | Derivative | Series B Preferred Stock | 2021-10-26 | C | D | 42,421 | — | 0 | I F-Prime Capital Partners Healthcare Advisors Fund IV LP | — · — to — | 4,465 Common Stock | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 7 | Derivative | Series B Preferred Stock | 2021-10-26 | C | D | 3,536,046 | — | 0 | I Impresa Fund III Limited Partnership | — · — to — | 372,215 Common Stock | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 8 | Derivative | Series B Preferred Stock | 2021-10-26 | C | D | 272,687 | — | 0 | I F-Prime Capital Partners Healthcare Fund IV LP | — · — to — | 28,703 Common Stock | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 9 | Derivative | Series A-1 Preferred Stock | 2021-10-26 | C | D | 6,521,739 | — | 0 | I F-Prime Capital Partners Healthcare Fund IV LP | — · — to — | 686,499 Common Stock | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| 10 | Derivative | Series A Preferred Stock | 2021-10-26 | C | D | 7,500,000 | — | 0 | I F-Prime Capital Partners Healthcare Fund IV LP | — · — to — | 789,473 Common Stock | (F1) On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |